CPhI Online

- Policy & Regulation

Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations

Gareth Carpenter — 23 Oct 2020

Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPhI Festival of Pharma

The ongoing COVID-19 pandemic means resiliency is likely to be built into US biologics manufacturing and diagnostics testing going forward, with the government likely to incentivize the building of excess capacity, according to former US Food and Drug Administration Commissioner, Dr Scott Gottlieb.

In a keynote address entitled The Landscape of Affordable Healthcare sponsored by DuPont Nutrition & Biosciences, Gottlieb told the virtual CPhI Festival of Pharma event that to address a lack of biologics manufacturing capacity, the solution would be to ask manufacturers and contract manufacturing organisations currently operating a number of bioreactors at maximal capacity to increase their fleet, but not operate them at full capacity.

Click here to read the article in full and watch the on-demand version

Related Content